23+ hour, 34+ min ago   (362+ words) clinicaltrialvanguard.com Iza-bren 2.5 mg/kg dose advances to Phase 3 in EGFR-mutated NSCLC Three dose levels entered a randomized expansion cohort; only one came out with a Phase 3 ticket. SystImmune and Bristol Myers Squibb will present at WCLC in Seoul on…...

3+ day, 23+ hour ago   (314+ words) The Clinical Trial Vanguard PSI CRO to Present Agile Models for Emerging Biotech at OCT New England Ninety-three percent repeat business and 15% revenue growth in a single year puts PSI CRO in an unusual position for a mid-size CRO: sponsors…...

3+ day, 23+ hour ago   (422+ words) The Clinical Trial Vanguard Insilico Medicine Begins Phase III Trial of AI-Discovered Drug Rentosertib for IPF Rentosertib just cleared a threshold no AI-discovered drug has reached before: 320 patients, 47 sites, 52 weeks of treatment in a randomized, double-blind, placebo-controlled Phase III. Insilico Medicine…...

3+ day, 23+ hour ago   (386+ words) The Clinical Trial Vanguard Seismic Pharmaceuticals Enrolls First Patient in Phase 3 Trial of Istaroxime for Cardiogenic Shock Cardiogenic shock kills roughly half the patients it reaches in the ICU, a mortality burden that has persisted for decades without a single…...

4+ day, 23+ hour ago   (336+ words) The Clinical Trial Vanguard Novartis Pays $50M Milestone as MRT-6160 Enters Phase 2 for Sjögren’s Disease A $50 million check is the clearest signal yet that Novartis believes VAV1 degradation works in humans. Monte Rosa Therapeutics triggered that milestone payment on September 8, 2026, when Novartis…...

4+ day, 23+ hour ago   (323+ words) The Clinical Trial Vanguard Nektar to Release 24-Week Off-Treatment Data for Rezpegaldesleukin in Alopecia Areata Nektar Therapeutics went quiet on September 8, 2026, and will stay that way until it releases the 24-week off-treatment follow-up data from its Phase 2b REZOLVE-AA study of…...

5+ day, 23+ hour ago   (347+ words) The Clinical Trial Vanguard Ascendis to Present Navepegritide Infant Trial Data at ESPE 2026 Sentinel cohort data from a pivotal infant trial rarely reach a major congress podium before the broader enrollment is complete, which makes Ascendis Pharma’s slot at ESPE…...

6+ day, 23+ hour ago   (334+ words) The Clinical Trial Vanguard Tekton Research Sites Enroll 60 Participants in Phase 2 Obesity Trial, Triple Goal Enrolling three times the planned number of participants is rare enough that it usually points to something structural, not just enthusiasm. Tekton Research’s San Antonio…...

1+ week, 23+ hour ago   (334+ words) The Clinical Trial Vanguard Roivant to Present Phase 2 Mosliciguat Data for PH-ILD on Tuesday Roivant and Pulmovant have 135 patients’ worth of Phase 2 data ready to show, and the number that matters most will be public Tuesday morning: how much mosliciguat…...

1+ week, 1+ day ago   (206+ words) The Clinical Trial Vanguard Tarsus Pharmaceuticals Acquires Alkeus, Gildeuretinol for Stargardt Disease Tarsus Pharmaceuticals paid an undisclosed sum to acquire Alkeus Pharmaceuticals and its lead asset, gildeuretinol (ALK-001), an oral investigational drug in Phase 3 development for Stargardt disease, a condition…...